---
figid: PMC11241496__ijms-25-06967-g002
pmcid: PMC11241496
image_filename: PMC11241496__ijms-25-06967-g002.jpg
figure_link: /pmc/articles/PMC11241496/figure/F2/
number: Figure 2
figure_title: Targeted therapies in RAS-RAF-MAPK pathway.
caption: 'Targeted therapies in RAS-RAF-MAPK pathway. Approved treatments and treatments
  under investigation in RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. Treatments in
  ongoing clinical trials are marked with an asterisk (not approved by the FDA). Abbreviations:
  T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan'
article_title: 'Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating
  Hallmarks of Cancer'
citation: Clara Salva de Torres, et al. Int J Mol Sci. 2024 Jul;25(13).
year: '2024'
pub_date: 2024-7-
epub_date: 2024-6-26
doi: 10.3390/ijms25136967
journal_title: International Journal of Molecular Sciences
journa_nlm_ta: Int J Mol Sci
publisher_name: MDPI
keywords:
- colorectal cancer
- hallmarks of cancer
- drug development
- cancer biology
- targeted therapies
- immune checkpoint inhibitors
---
